BiotechTube

NS2 + Prednisolone acetate ophthalmic suspension (1%)

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non-infectious Anterior Uveitis

Conditions

Non-infectious Anterior Uveitis

Trial Timeline

Mar 1, 2015 → Apr 1, 2016

NCT ID
NCT02406209

About NS2 + Prednisolone acetate ophthalmic suspension (1%)

NS2 + Prednisolone acetate ophthalmic suspension (1%) is a phase 2 stage product being developed by Aldeyra Therapeutics for Non-infectious Anterior Uveitis. The current trial status is completed. This product is registered under clinical trial identifier NCT02406209. Target conditions include Non-infectious Anterior Uveitis.

What happened to similar drugs?

2 of 7 similar drugs in Non-infectious Anterior Uveitis were approved

Approved (2) Terminated (2) Active (3)
✅AdalimumabAbbVieApproved
❌AIN457 + PlaceboNovartisPhase 3
❌AIN457 + AIN457 + AIN457 + PlaceboNovartisPhase 3
✅Topical Prednisolone Acetate 1%Ocular TherapeutixApproved
🔄FAI insert + Sham injectionEyePoint PharmaceuticalsPhase 3
🔄FAI Insert administered using the Mk II inserter + FAI Insert administered using the Mk I inserterEyePoint PharmaceuticalsPhase 3
🔄ADX-102 Ophthalmic Solution (0.5%) + Vehicle of ADX-102 Ophthalmic SolutionAldeyra TherapeuticsPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02406209Phase 2Completed

Competing Products

10 competing products in Non-infectious Anterior Uveitis

See all competitors
ProductCompanyStageHype Score
AdalimumabAbbVieApproved
43
LFG316 + Conventional TherapyNovartisPhase 2
35
AIN457 + PlaceboNovartisPhase 3
32
AIN457 + AIN457 + AIN457 + PlaceboNovartisPhase 3
32
AIN457 + AIN 457 + AIN457NovartisPhase 2
35
ESK-001AlumisPhase 2
21
Topical Prednisolone Acetate 1%Ocular TherapeutixApproved
33
FAI insert + Sham injectionEyePoint PharmaceuticalsPhase 3
34
FAI Insert administered using the Mk II inserter + FAI Insert administered using the Mk I inserterEyePoint PharmaceuticalsPhase 3
34
ADX-102 Ophthalmic Solution (0.5%) + Vehicle of ADX-102 Ophthalmic SolutionAldeyra TherapeuticsPhase 3
30